SWOG clinical trial number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Open
Phase
Accrual
24%
Abbreviated Title
Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL
Status Notes
Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
Activated
02/23/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS
Research committees
Lymphoma
Treatment
Mosunetuzumab
Polatuzumab vedotin
Patient Study Materials
Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary
Other Study Materials
Eligibility Criteria Expand/Collapse
*Please review Section 5: Eligibility of the protocol for eligibility criteria.*
Publication Information Expand/Collapse
2022
A non-factorial analysis of a factorial Phase II trial design to evaluate single agent and combination consolidation therapies following CD19 CAR T-cell therapy for relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL): SWOG-S2114
Other Clinical Trials
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase